Compare SOBR & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | HCWB |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.0M |
| IPO Year | 2008 | 2021 |
| Metric | SOBR | HCWB |
|---|---|---|
| Price | $1.11 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 16.7M | ★ 25.6M |
| Earning Date | 04-10-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | $437,421.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.23 |
| Revenue Growth | ★ 105.62 | N/A |
| 52 Week Low | $0.48 | $0.25 |
| 52 Week High | $5.27 | $8.75 |
| Indicator | SOBR | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 62.52 |
| Support Level | $0.57 | $1.49 |
| Resistance Level | $2.25 | $3.78 |
| Average True Range (ATR) | 0.33 | 0.57 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 2.79 | 44.44 |
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.